What more can we learn from DTC ad­ver­tis­ing? FDA's OPDP pro­pos­es new re­search

3 years ago
Pharma
FDA+

Sanofi us­es cre­ative cam­ou­flage in physi­cian-tar­get­ed cam­paign for po­ten­tial can­cer bio­mark­er

3 years ago
Pharma
Marketing

Re­al-time re­views for cell and gene ther­a­pies? Pfiz­er to FDA: Yes, please

3 years ago
Cell/Gene Tx
FDA+

Covid-19 roundup: Sh­iono­gi’s an­tivi­ral pill hits the mark; Ocu­gen strikes deal for in­tranasal vac­cine

3 years ago
Coronavirus

Wyss In­sti­tute spin­out looks to re­vamp drug de­vel­op­ment for CNS dis­eases — with CRISPR tad­poles

3 years ago
Startups
R&D

TCR²'s ga­vo-cel sur­vives a PhI test. Now it's head-first in­to PhII with a half-dozen par­tial re­spons­es

3 years ago
R&D

Gami­da Cell prices its fol­low-on pub­lic of­fer­ing at $20M; Rally­bio touts Phase Ib da­ta for mon­o­clon­al an­ti­body

3 years ago
News Briefing

J&J de­buts Ken­vue as new name for $15B con­sumer health busi­ness spin­off

3 years ago
Pharma
Marketing

'Struc­ture, beau­ty and clar­i­ty': With seed fi­nanc­ing, Kalei­do­scope aims to syn­chro­nize R&D teams

3 years ago
Financing
Startups

Bris­tol My­ers got the first TYK2 ap­proval. Fra­zier’s new biotech Su­do hopes to get many more

3 years ago
Financing
Startups

CMS as gate­keep­er: Why lecanemab is sim­i­lar but al­so very dif­fer­ent from Aduhelm

3 years ago
Pharma

For­mer No­var­tis drug for ul­tra-rare dis­ease gets speedy FDA re­view

3 years ago
FDA+

A new ADC biotech looks to re­vive se­cre­tive plat­form, se­cures Big VC back­ing

3 years ago
Financing
Startups

Bio­gen, Ei­sai re­fresh amy­loid hy­poth­e­sis with PhI­II show­ing Alzheimer's med slows cog­ni­tive de­cline

3 years ago
R&D

New Jer­sey biotech nets $50M+ BAR­DA con­tract for res­pi­ra­to­ry can­di­date

3 years ago
R&D
Pharma

Up­dat­ed: Study iden­ti­fies Covid-19 pa­tients with mu­ta­tions in­di­cat­ing remde­sivir re­sis­tance

3 years ago
Coronavirus

FDA's OTAT morphs in­to the Of­fice of Ther­a­peu­tic Prod­ucts as new funds await

3 years ago
FDA+

Up­dat­ed: Does R&D spend link to fi­nal mar­ket price? Aca­d­e­mics say 'no' in new pa­per

3 years ago
Pharma

Ab­b­Vie teams up with Shut­ter­stock to re­de­fine beau­ty in lat­est aes­thet­ics cam­paign

3 years ago
Pharma
Marketing

Genen­tech de­buts next it­er­a­tion of its Ocre­vus MS cam­paign, tar­get­ing GenZ and His­pan­ic au­di­ences

3 years ago
Pharma
Marketing

Man­u­fac­tur­ing sites in Ger­many and Chi­na hit with warn­ing let­ters over QC and clean­ing is­sues

3 years ago
Pharma
FDA+

From Covid ad boom to en­dem­ic: Track­ing TV ads from first rush of brand ca­ma­raderie to to­day’s phar­ma boost­ers

3 years ago
Pharma
Marketing

UK reg­u­la­tors cau­tion against switch­ing be­tween com­mon AD­HD meds

3 years ago
Pharma

Mar­ket­ingRx roundup: Mod­er­na en­cour­ages fall boost­ers; Roche's Genen­tech amps its STEM di­ver­si­ty pro­gram

3 years ago
Pharma
Marketing
First page Previous page 454455456457458459460 Next page Last page
A service from the Financial Times